Company Will Present New Scientific Data at the Meeting April 2-6, 2011
In Orlando, Florida
MONTREAL, April 1 /CNW Telbec/ - Sunshine Biopharma, Inc. (OTCBB Ticker
Symbol: SBFM) a development stage pharmaceutical company focused on the
research, development and commercialization of drugs for the treatment
of various forms of cancer, today announced that they will be
presenting scientific data at the American Association for Cancer
Research Meeting April 2-6, 2011 in Orlando Florida.
The DNA repair enzyme Topoisomerase II has been recognized in the
oncology field as a clinically important therapeutic target for a
variety of cancers. Inhibition of Topoisomerase II activity is
essential in the fight against aggressive types of cancer, including
multi-resistant breast cancer.
Sunshine Biopharma has developed a new compound, Adva-27a, which acts as
a specific inhibitor of Topoisomerase II. The data, which will be
presented at the Meeting by the Company's research collaborator, Dr.
Susannah Gal of Binghamton University (State University of New York),
show that Adva-27a and its derivative, Adva-32a, are significantly more
effective at killing aggressive cancer cells than Etoposide, the drug
currently in use.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, including statements as to revenue projections, business
strategy, outlook, objectives, future milestones, plans, intentions,
goals, future financial conditions, future collaboration agreements,
the success of the Company's development, events conditioned on
stockholder or other approval, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made.
SOURCE Sunshine Biopharma Inc.
For further information:
Mr. Camille Sebaaly, CFO
Sunshine Biopharma Inc.